Does Abeona Therapeutics (NASDAQ:ABEO) Look Attractive Now? Citigroup Initiates Coverage

Abeona Therapeutics

Abeona Therapeutics

With 1.30 million shares average volume, it will take short sellers 5 days to cover their ABEO's short positions. 1,718,690 shares have been traded. The insider now holds 100,000 shares of Abeona Therapeutics Inc. It has outperformed by 134.32% the S&P500. Over the past month the firm's stock is 42.50%, 121.67% for the last quarter, 311.34% for the past six-months and 190.82% for the previous year. GE's profit will be $4.30 billion for 11.80 P/E if the $0.50 EPS becomes a reality.

In terms of Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The company's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA).

As of the last earnings report the EPS was $-0.61 and is estimated to be $-0.68 for the current year with 40,287,000 shares outstanding.

Abeona Therapeutics (NASDAQ:ABEO) has average revenue estimates of $230 Million, compared to low analyst estimates of $190 Million and high estimates of $300 Million for the current quarter. BidaskClub upgraded Abeona Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, July 12th. The rating was maintained by H.C. Wainwright on Thursday, August 24 with "Buy". The rating was maintained by Maxim Group on Tuesday, July 18 with "Buy". The short interest to Abeona Therapeutics Incorporated's float is 32.66%.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Tuesday, August 15th. Maxim Group initiated Abeona Therapeutics Inc (NASDAQ:ABEO) on Wednesday, December 16 with "Buy" rating.

10/10/2017-Citigroup Inc. initiated coverage with a Buy rating.

Among 5 analysts covering Swiss Re (OTCMKTS:SSREY), 0 have Buy rating, 3 Sell and 2 Hold. Jefferies maintained it with "Buy" rating and $1100 target in Thursday, June 1 report. The firm earned "Buy" rating on Thursday, April 27 by Jefferies.

Investors sentiment decreased to 1.97 in Q2 2017. Its down 0.03, from 0.82 in 2017Q1. ADVISORS LP with 1.68 million shares, BLACKROCK INC. with 1.23 million shares, and VANGUARD GROUP INC with 1.08 million shares. Gateway Advisory Lc reported 54,718 shares stake. Parkwood Llc has 135,000 shares for 0.27% of their portfolio. Golub Gru owns 32,361 shares or 0.08% of their United States portfolio. Piermont Capital Management Inc., a Missouri-based fund reported 18,705 shares.

About 48,069 shares traded. There were 9 sold out positions, amounting to 852,383 shares. Snow Mgmt LP holds 0.03% or 22,486 shares in its portfolio. Allianz Asset Management Gmbh now owns 122,692 shares worth $785,000. Jennison Assocs Ltd Liability stated it has 0.08% in General Electric Company (NYSE:GE). Bnp Paribas Arbitrage Sa stated it has 10,199 shares or 0% of all its holdings. Advisors Lp, which now holds $29.48 million worth of this stock and that ownership represents almost 3.9% of its market capitalization. Therefore 71% are positive. Swiss Re had 8 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has "Market Perform" rating given on Friday, February 19 by Wells Fargo. Orrstown Financial Services Inc sold 28,163 shares as General Elec Co Com (GE)'s stock declined 7.64%. The mean rating score for this stock is at 3.00. The rating was maintained by Keefe Bruyette & Woods on Friday, September 22 with "Buy".

10/6/2017-Cantor Fitzgerald Reiterated Rating of Buy. On Friday, November 6 the stock rating was maintained by Deutsche Bank with "Buy". The company was maintained on Tuesday, August 29 by Maxim Group.